
CLAIMS

1. A 2',2-bisthiazole non-nucleoside compound of formula I:



I

wherein,

R_1 and R_2 are each independently H or C_1-C_4 alkyl,

R_3 is C_1-C_{46} alkyl substituted by at least one hydroxyl group~~, C_1-C_6 alkyl substituted by at least one C_1-C_6 alkoxyl group, C_1-C_6 alkyl substituted by~~ or at least one halogen atom, or C_2-C_6 alkenyl~~, or C_2-C_6 alkenyl substituted by at least one hydroxyl group or at least one halogen atom,~~

X is halogen atom.

2. The 2',2-bisthiazole non-nucleoside compound of claim 1, wherein R_1 is H, methyl or ethyl, and R_2 is H.


3. The 2',2-bisthiazole non-nucleoside compound of claim 1 or 2, wherein R_3 is C_1-C_{45} alkyl substituted by one ~~or two~~ hydroxyl group~~s~~, C_1-C_{45} alkyl substituted by one ~~or two C_1-C_4 alkoxyl groups, C_1-C_5 alkyl substituted by one~~ fluorine, chlorine or bromine atom, or methylpropenyl~~, methylolpropenyl or fluoromethylpropenyl~~.

4. The 2',2-bisthiazole non-nucleoside compound of ~~any one of~~ claim~~s~~ 1 ~~to~~or ~~3~~2, wherein R_3 is C_4 alkyl substituted by one ~~or two~~ hydroxyl group~~s~~, ~~C_4 alkyl substituted by one or two C_1-C_4 alkoxyl groups,~~ C_4 fluoroalkyl, or 2-methylpropenyl~~, 2-methylolpropenyl or 2-fluoromethylpropenyl~~.


5. The 2',2-bisthiazole non-nucleoside compound of ~~any one of~~ claim~~s~~ 1 ~~to 4~~or 2, wherein X is F.

6. The 2',2-bisthiazole non-nucleoside compound of claim 1 or 2, wherein X is F at 4-site.


~~6~~7. The 2',2-bisthiazole non-nucleoside compound of ~~any one of~~ claim~~s~~ 1 ~~to 5~~or 2, which is one selected from the group consisting of:




391-1




391-2




391-3




393-1




393-2




373




389




391-F




407




405-1




Me-373



Me-391-1




Me-373



Me-393-1


~~7~~8. A method of preparing the 2',2-bisthiazole non-nucleoside compound of ~~any one of~~ claim~~s~~ 1 ~~to 6~~or 2 following scheme III, scheme IV or scheme V:



4 I

Scheme III

the intermediate methyl 2',2-bisthiazolecarboxylate **4** reacts with a halogenated benzylamine as a nucleophilic reagent in ethylene glycol as a solvent at an elevated temperature to produce the 2',2-bisthiazole non-nucleoside compound, or




4

I

Scheme IV

the intermediate methyl 2',2-bisthiazolecarboxylate **4** is converted through hydrolyzation into a corresponding acid, which reacts with oxalylchloride to produce an acyl chloride, and the acyl chloride then reacts with a halogenated benzylamine to produce the 2',2-bisthiazole non-nucleoside compound, or



4

I

Scheme V

the intermediate methyl 2',2-bisthiazolecarboxylate **4** is converted through hydrolyzation into a corresponding acid, which reacts with a halogenated benzylamine in the presence of EDCI (1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride) as a condensing agent to produce the 2',2-bisthiazole non-nucleoside compound,

wherein, the definitions of R_1, R_2, R_3 and X in above schemes are ~~as defined~~the same as in claim 1 or 2.

~~8~~9. A pharmaceutical composition ~~against~~for treating viral hepatitis B and/or viral hepatitis C, which comprises a therapeutically effective amount of ~~one or more of~~ the 2',2-bisthiazole non-nucleoside compounds according to ~~any one of~~ claim~~s~~ 1 ~~to 6~~or 2 as an active component and optionally pharmaceutically acceptable common adjuvants.

~~9~~10. A method for preparing a drug for the treatment of hepatitis B and/or hepatitis C by using~~Use of~~ the 2',2-bisthiazole non-nucleoside compound of ~~any one of~~ claim~~s~~ 1 or 2~~ to 6 in the preparation of a medicament for the treatment of hepatitis B and/or hepatitis C to a subject suffering from hepatitis B or hepatitis C~~.

~~10. The 2',2-bisthiazole non-nucleoside compound of claim 5, wherein F is at 4-site.~~